Maximum Immediate-Release Amphetamine/Dextroamphetamine Dosing
The FDA-approved maximum daily dose for Adderall IR in adults is 40 mg per day, typically divided into 2-3 doses, with no single dose exceeding 20 mg. 111
Current Dosing Context
Your patient is currently taking 30 mg twice daily (60 mg/day total), which exceeds the FDA-approved maximum daily dose by 50%. This is an off-label dosing regimen.
Key Dosing Parameters
FDA-Approved Limits
- Maximum total daily dose: 40 mg/day
- Typical dosing frequency: 2-3 times daily
- Maximum single dose: 20 mg per administration (implied by typical BID-TID dosing of 40 mg total)
Evidence Against Higher Doses
Recent high-quality evidence from a 2026 Lancet Psychiatry network meta-analysis demonstrates that doses exceeding FDA recommendations show a plateau or even decline in efficacy 22. Specifically:
- Amphetamine efficacy peaks around 25 mg/day in adults
- Doses beyond FDA limits provide diminishing returns with increased adverse effects
- Higher doses are associated with significantly increased dropout rates due to adverse events (RR 2.69,95% CI 1.63-4.45) 2
Cardiovascular and Safety Concerns
Amphetamines consistently increase blood pressure and heart rate at all doses, with sustained effects even after 8+ weeks of use 3:
- Systolic BP increases by 1.93 mmHg (95% CI 1.54-2.31)
- Diastolic BP increases by 1.84 mmHg (95% CI 1.51-2.16)
- Heart rate increases by 3.71 bpm (95% CI 3.27-4.14)
Prolonged use at high doses carries risk of cardiomyopathy through oxidative stress, sympathetic overactivity, and direct myocardial toxicity 4.
Clinical Recommendation
Your patient should be tapered down to the FDA-approved maximum of 40 mg/day (e.g., 20 mg twice daily). The current 60 mg/day regimen:
- Exceeds evidence-based efficacy thresholds with no demonstrated additional benefit
- Increases cardiovascular risk without offsetting therapeutic gains
- Violates FDA-approved dosing parameters established for safety
If Inadequate Response at FDA-Approved Doses
Rather than exceeding 40 mg/day, consider:
- Switching to lisdexamfetamine (prodrug with smoother pharmacokinetics)
- Adding non-stimulant adjuncts
- Reassessing diagnosis and comorbidities
- Optimizing behavioral interventions
The evidence does not support exceeding FDA-approved doses as a general strategy, as any marginal benefit is outweighed by cardiovascular risks and adverse effects 22.